CHOP (DDIT3) Breakapart
Myxoid liposarcoma (MLS) is the most common subtype of liposarcoma1. The TLS-CHOP (FUS-DDIT3) t(12;16)(q13.3;p11) fusion gene, firstly described by Turc-Carel et al. in 19862, is now well established and is present in at least 95% of MLS3.
In rare cases, an EWS-CHOP (EWSR1-DDIT3) t(12;22)(q13;q12) translocation has been described4. The transcription factor gene, CHOP (DDIT3) (CREBP-homologous protein/DNA damage inducible transcript 3), is a negative regulator of adipocyte differentiation5.
The TLS (Translocated in Liposarcoma)6 or FUS7 gene is a nuclear RNA-binding protein with extensive sequence similarity to EWS. The TLS-CHOP protein interferes with adipocyte differentiation and favours proliferation over terminal differentiation4.
It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center
1. Enzinger and Weiss, Soft Tissue Tumors 3rd Ed. St Louis; MO:Mosby, 1995
2. Turc-Carel et al., Can Genet Cytogenet 1986;23:291-9
3. Mitelman, Catalog of chromosome aberrations in cancer. 5th Ed. 1995 New York: WileyLiss, Inc. 1994
4. Antonescu et al., Clin Canc Res 2001;7:3977-87
5. Hunag et al., Biol Open. 2012 Aug 15;1(8):705-10
6. Crozat et al., Nature 1993;363:640-4
7. Rabbitts et al., Nat Genet 1993;4:175-80
- Area of Interest*
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.